Cutting-edge talks from today’s specialty experts attract attendees to the DF’s annual CME meeting: Clinical Symposia—Advances in Dermatology.

Mohs for Melanoma

Dr. Bordeaux’s key takeaway message is that Mohs decreases the local recurrence of melanoma and helps reduce the number of re-excisions that patients undergo due to positive margins


NCCN recommends Mohs as the first-line therapy for DFSP

Climate Change and Dermatology

Dr. Davis presented on climate change and dermatology. He spoke about climate change definitions, consequences, effects on the skin, effects on dermatology, and what dermatologists can do individually and as a group to address climate change.

When to Suspect Immunodeficiency

Dr. Treat presented three types of clinical scenarios suggesting immunodeficiency: primary skin findings of infections that are unusual, opportunistic, or exuberant; secondary skin findings of eczematous or granulomatous changes; and immunosuppressed groups.

The Curious Syndrome of Erythromelalgia

Dr. Davis presented his medical experiences of patients with erythromelalgia. He typically sees 3-5 new patients with erythromelalgia per week.

New Insights from Genetic Analysis of Cutaneous Adnexal Tumors

Dr. North presented new insights from genetic analysis of cutaneous adnexal tumors.

Clues for Diagnosing Uncommon Inflammatory Diseases

Dr. North presented cases of uncommon inflammatory skin diseases and the clues for diagnosis.

Pediatric Connective Tissue Disease: Cases that Taught Me a Lesson

Dr. Chiu presented 4 cases of pediatric connective tissue diseases and the lessons learned from each case.

New Topical Therapies for Psoriasis and Atopic Dermatitis

Dr. Bhutani presented new topical therapies for psoriasis and atopic dermatitis, including tapinarof, roflumilast, and ruxolitinib.

Caring for the Patient with Cutaneous Immune-Related Events

Dr. Chen presented new research on the management of dermatologic immune-related adverse events (D-irAEs), including high-yield tips, and discussed potential future implications and therapeutic care of patients who receive immune checkpoint inhibitors (ICIs).